The protective effects of ursodeoxycholic acid and the selective cyclooxygenase-2 inhibitor celecoxib on liver damage in an experimental cholestasis model

Journal Title: UNKNOWN - Year 2019, Vol 2, Issue 2

Abstract

Aim: Cholestasis leads to liver cell death, fibrosis, cirrhosis, and eventually liver failure. Ursodeoxycholic acid (UDCA) is the only Food and Drug Administration-approved treatment for cholestatic disorders. Hepatic cyclooxygenase-2 (COX-2) expression increases in various chronic liver diseases caused either by viruses or toxins. The present study was conducted to investigate the effects of UDCA and the selective COX-2 inhibitor celecoxib on inflammation and fibrogenesis in a rat model of cholestasis induced by bile duct ligation (BDL). Methods: Fifty Sprague–Dawley rats that underwent common BDL for 21 days were assigned to one of five treatment groups (sham-operation, BDL, daily UDCA treatment following BDL, daily celecoxib treatment following BDL, and daily celecoxib and UDCA combination treatment following BDL). Serum and liver samples were collected after 21 days. Fibrosis, ductular proliferation, and portal inflammation were scored in liver samples. Liver function tests were evaluated. Results: In comparison with the control group, the BDL group showed hepatic damage as evidenced by elevation in serum biochemical and histological changes such as ductular reaction, fibrosis, and inflammation. These pathophysiological changes were attenuated by chronic UDCA and selective COX-2 inhibitor celecoxib supplementation. Conlusion: Our findings indicate that the addition of Celecoxib to UDCA reduces liver inflammation and fibrosis and might be an effective supplemental therapy with UDCA for cholestatic diseases. The beneficial effects of chronic UDCA and Celecoxib supplementation may be associated with their potential cytoprotective, anti-oxidative and anti-inflammatory effects.

Authors and Affiliations

Adem Kucuk, Hulya Ozturk

Keywords

Related Articles

The association of serological tests and anemia in celiac disease

Aim: Celiac disease (CD) is a common immune-mediated enteropathy caused by gluten. These patients may apply with many different clinical forms. The aim of this study is to determine the association of serolog...

Roles of the systemic inflammatory response biomarkers in the diagnosis of cancer patients with solid tumors

Aim: Cancer is still considered as one of the leading causes of mortality worldwide. Various tumor factors have been used for the diagnosis and follow-up of solid tumors; however, their clinical features remains controve...

Evaluation of the resistance patterns of Mycobacterium tuberculosis complex strains to antituberculous drugs

Aim: To determine the resistance profile of Mycobacterium tuberculosis complex (MTBC) strains to first-line antituberculous drugs. Methods: A total of 138 patients with MTBC growth from 2008-2018 were evaluated retrospec...

Effectiveness of balneotherapy in knee osteoarthritis

Aim: We aimed to investigate the effects of balneotherapy on knee osteoarthritis in present randomized controlled single blind clinical trial. Methods: Patients with knee osteoarthritis according to ACR crit...

Frequency of uveitis and its associations with HLA B27 in ankylosing spondylitis patients

Aim: To investigate the prevalence of uveitis in ankylosing spondylitis (AS) patients and its relationship with HLA B27. Methods: The data of 95 patients with AS who admitted to Tokat Gaziosmanpaşa University Internal Me...

Download PDF file
  • EP ID EP496258
  • DOI 10.30714/j-ebr.2019250350
  • Views 130
  • Downloads 0

How To Cite

Adem Kucuk, Hulya Ozturk (2019). The protective effects of ursodeoxycholic acid and the selective cyclooxygenase-2 inhibitor celecoxib on liver damage in an experimental cholestasis model. UNKNOWN, 2(2), 50-61. https://europub.co.uk/articles/-A-496258